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We applied double gradient-denaturing gradient gel electrophoresis (DG-DGGE) for the rapid detection of
rifampin (RMP) resistance from rpoB PCR products of Mycobacterium tuberculosis isolates and clinical sam-
ples. The results of this method were fully concordant with those of DNA sequencing and susceptibility testing
analyses. DG-DGGE is a valid alternative to the other methods of detecting mutations for predicting RMP
resistance.
Rifampin (RMP) resistance in mycobacteria is most fre-
quently due to point mutations as well as small insertions and
deletions located in an 81-nucleotide region of the rpoB gene
encoding the b-subunit of RNA polymerase (7, 10, 12, 19, 24).
The genotype assessment of RMP resistance offers a number
of advantages over conventional culture susceptibility testing.
(i) The turnaround time is days, rather than weeks or months.
(ii) It can be automated. (iii) It leads to fewer laboratory bio-
hazards.
This study made use of a modified version of the original
denaturing gradient gel electrophoresis (DGGE) methodology
described by Fisher and Lerman (5) and Myers et al. (14). In
order to obtain maximum DGGE sensitivity, heteroduplexes of
wild-type and mutant sequences were generated, and to im-
prove the analysis of these molecules (which often produce
curtains and smears instead of sharp zones), we used a second
(porous) gradient over the denaturing gradient (3, 6). This
double gradient-DGGE (DG-DGGE) was used to detect mu-
tations in the rpoB region of the PCR products obtained from
mycobacterial isolates and clinical samples.
(Part of this work was presented at the 38th Interscience
Conference on Antimicrobial Agents and Chemotherapy, San
Diego, Calif., 24 to 27 September 1998 [18]).
We processed 117 Mycobacterium tuberculosis (81 RMP-re-
sistant and 36 RMP-susceptible) clinical strains; RMP-suscep-
tible H37Rv M. tuberculosis ATCC 27294 was used as a control.
RMP susceptibility was determined by the BACTEC radiomet-
ric method (8). The critical RMP concentration in BACTEC
12B vials was 2 mg/ml. The clinical isolates were classified on
the basis of IS6110 restriction fragment length polymorphism
(RFLP) pattern subtypes (22). Two groups of clinical speci-
mens were also processed by means of PCR–DG-DGGE: (i)
84 IS6110 PCR-positive clinical specimens from a variety of
anatomical sources obtained from 62 patients with microbio-
logically proved tuberculosis, and (ii) 48 cerebrospinal fluid
(CSF) samples collected from 28 patients with confirmed or
highly probable tuberculous meningitis.
Bacterial suspensions containing approximately 105 acid-fast
bacilli in 250 ml of sterile deionized H2O and 250 to 500 ml of
each clinical specimen underwent DNA extraction by the chao-
trope-silica method (2). Aliquots of DNA were used for time
release PCR (1) of the rpoB region (GenBank accession no.
L27989) by means of primers TR9 (59-TCGCCGCGATCAA
GGAGT) and rpoB-2643GC (59-CGTCGCTAACCACGCC
GT). The latter oligonucleotide carries an additional 30 bp of
a GC-rich sequence at its 59 end. The annealing temperatures
were 63°C for the first 20 cycles and 61°C for the subsequent 30
cycles. The presence of a 339-bp band on a 1.8% agarose gel
indicated successful amplification. The heteroduplex mole-
cules were obtained as previously described (3).
In order to obtain some indications for the best choice of the
DNA sequence containing the rpoB core region susceptible to
DGGE analysis, we used a computer algorithm (MacMelt 1.0;
Bio-Rad Laboratories, Hercules, Calif.) derived from the orig-
inal computer program developed by Lerman and Silverstein
(11).
The denaturing gradient gels were electrophoresed in an
apparatus purchased from Bio-Rad Laboratories (D GENE
Denaturing Gel Electrophoresis System); a two-chamber gra-
dient maker (Pharmacia, Uppsala, Sweden) was used to create
the linear-gradient gels. The PCR products were electropho-
resed in a colinearly increasing double gradient of 50 to 75%
denaturant and 6.5 to 12% polyacrylamide gels in 13 TAE
buffer (203 TAE buffer is 0.8 M Tris base–0.4 M sodium
acetate–0.02 M EDTA, pH 7.4) at a constant temperature of
60°C at 50 V overnight. The gels were stained with Sybr green
II (FMC Bio Products, Rockland, Maine) and photographed
with a UV transilluminator.
The rpoB PCR products were sequenced with the same
primers in an automated DNA sequencer (model 377; Applied
Biosystems, Foster City, Calif.). Both strands were sequenced.
RFLP analysis of the 117 clinical isolates revealed 93 differ-
ent patterns corresponding to single isolates, multiple samples
from the same patient, or epidemic strains (Table 1). DG-
DGGE analysis revealed altered homoduplex mobility and/or
heteroduplex molecule formation in the PCR products of all of
the RMP-resistant strains. Fourteen different patterns were
observed in these samples, consisting of sets of three or four
bands when heteroduplexes were produced (Fig. 1). The PCR
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products of the RMP-susceptible strains did not show any
heteroduplex formation or abnormal homoduplex mobility.
DNA sequencing results confirmed the DG-DGGE results.
Fourteen alleles were detected in the RMP-resistant strains
(Table 1). Eleven of the mutations found in this study have
already been reported in the literature. Four new mutations
were found in three strains: one in codon 522 in one strain, two
in codons 513 and 562 in another strain, and a deletion of
codons 511 to 513 in the third strain (codon 510 changed to
CAA still codes for Gln) (Table 1).
Amplified rpoB products were generated from 54 of 84
IS6110 PCR-positive specimens (64.3%) collected from 42
(67.7%) of the 62 patients with non-central nervous system
(non-CNS) tuberculosis (Table 2). From all 30 of the spec-
imens with the wild-type DG-DGGE pattern, a RMP-sus-
ceptible strain was cultured. From the 24 specimens with an
abnormal DG-DGGE pattern, 1 RMP-susceptible and 23
RMP-resistant strains were cultured. In the case of discor-
dance, DG-DGGE analysis showed the presence of at least two
clones, one of which carried a mutation in the rpoB gene; as a
matter of fact, that heteroduplex formation was observed with-
out mixing with wild-type DNA. Direct DNA sequencing
showed a single point mutation located in codon 526 reading
GAC instead of CAC (His3Asp) or in codon 531 reading
TTG instead of TCG (Ser3Leu), in all of the strains with an
abnormal DG-DGGE pattern and a resistant phenotype.
Table 3 summarizes the results obtained by processing the
CSF samples. In brief, the results of PCR–DG-DGGE analysis
of the CSF specimens correlated in all cases with the RMP
phenotypes of isolates cultured from the same patients. No
differences in the DG-DGGE patterns of the amplified prod-
ucts obtained from suspensions of M. tuberculosis isolates and
from CSF specimens collected from the same patients were
observed (data not shown). No mutations in the rpoB segment
sequenced from the RMP-susceptible strains were revealed,
whereas three different kinds of nucleotide substitution were
found in all of the RMP-resistant strains. The mutations were
located in codon 531, coding TTG instead of TCG (Ser3Leu),
and in codon 526, coding GAC or TAC instead of CAC
(His3Asp or His3Tyr).
The detection of RMP resistance at the genotype level by
molecular biology techniques designed to search for rpoB gene
mutations has been the subject of various publications since
1993 (4, 7, 10, 15, 17, 19–21, 23, 24). Once these methods have
been optimized and partially automated, it is possible that they
will be adopted at least by reference laboratories (21).
The main aim of this study was to verify the applicability of
DG-DGGE to investigating the sequence variations arising in
the core region of rpoB. In comparison with other methods,
DG-DGGE has a number of practical advantages. It is cer-
tainly less laborious than the manual single-strand conforma-
tion polymorphism (SSCP) method used by us in a previous
study (17) because it does not require the casting of ultrathin
gels or the use of radioactive isotopes. Furthermore, DG-
DGGE is performed by means of a relatively inexpensive ma-
chine that allows controlled experimental conditions and op-
timum reproducibility.
TABLE 1. Sequence analysis of the rpoB gene of M. tuberculosis isolates from a region in Northern Italy
RMP phenotype Affected codon(s)(mutation)a Amino acid change(s) No. of isolates
No. of individual strains
(frequency [%])
Resistantb 533 (CCG) Leu3Pro 1 1
Resistant 531 (TTG) Ser3Leu 43 35 (57.4)
Resistant 531 (TGG) Ser3Trp 1 1
Resistant 526 (GAC) His3Asp 14 4 (6.6)
Resistant 526 (TAC) His3Tyr 7 6 (9.8)
Resistant 526 (CTC) His3Leu 1 1
Resistant 526 (AAC) His3Asn 1 1
Resistantc 522 (CAG) Ser3Gln 1 1
Resistant 516 (TAC) Asp3Tyr 6 5 (8.2)
Resistant 516 (GGC) Asp3Gly 1 1
Resistant 516 (GTC) Asp3Val 2 2
Resistantd 512 (ACC), 526 (AAC) Ser3Thr, His3Asn 1 1
Resistante 513 (GAA), 562 (GCA) Gln3Glu, Glu3Ala 1 1
Resistant 510–513 deletion (GCTGAGCCA) Leu-Ser-Gln deletion 1 1
Susceptible None None 36 32
Total 117 93
a Numbers correspond to E. coli numbering system for the RNA polymerase b-subunit. Nucleotide substitutions are underlined.
b Resistant to RMP at 2 mg/ml by the BACTEC method.
c Two mutations in the same codon.
d Two mutations in separate codons.
e Two mutations in separate codons, one of which is located outside the rpoB core region.
TABLE 2. Direct detection of M. tuberculosis rpoB in 84 clinical







Respiratory (39) 1 1 1 1
Respiratory (5) 2 1 1 1
Respiratory (1) 2 2 1 1
Respiratory (15) 1 1 1 2
Respiratory (7) 2 1 1 2
Respiratory (5) 2 2 1 2
Nonrespiratory GW and L (6) 1 1 1 1
Nonrespiratory GW, PE, and U (3) 2 1 1 1
Nonrespiratory GW and L (2) 1 1 1 2
Nonrespiratory PE (1) 2 2 1 2
a Respiratory specimens include sputum and bronchial wash or lavage speci-
mens. Abbreviations: GW, gastric wash; L, lymph node; PE, pleural effusion; U,
urine.
b 1, positive; 2, negative.
c A previously described homemade nested PCR protocol was used to obtain
these results (16).
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By using this procedure, the amplified products obtained
from all of the RMP-resistant strains unequivocally demon-
strated homoduplex mobility alterations and/or the formation
of heteroduplex molecules expressing the presence of muta-
tions. This result was confirmed by automated sequence anal-
ysis of the entire sequence under investigation.
The mutations in the rpoB core region found in this study
affect 7 of the 11 amino acids involved and constitute about
one-third of the mutations found in that region previously
reported in the literature; nevertheless, in terms of frequency,
the mutations detected by us represent about 84% of the al-
terations reported in a recent review (13). Moreover, the in-
volved codons found in this study are uniformly distributed
throughout the rpoB core region, thus suggesting that DG-
DGGE analysis may be capable of detecting mutations located
anywhere in this sequence.
A RMP-resistant strain of our collection was shown have a
double mutation in the rpoB gene, one of which (Glu562Ala)
FIG. 1. DG-DGGE analysis. Photograph of DG-DGGE patterns showing the electrophoretic mobility of homoduplex and heteroduplex PCR fragments from
RMP-susceptible H37Rv M. tuberculosis ATCC 27294 (lanes 3, 6, 9, 12, 17, 22, 29, 30, and 36) and RMP-resistant strains (all other lanes). For each resistant strain,
both the homoduplex and heteroduplex patterns are shown. Thirteen of the 14 alleles listed in Table 1 are shown (mutation affecting codon 533 is not shown). Wt, wild
type; Del, deletion.
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was located outside the core region. The significance of this
mutation in the genesis of RMP resistance in M. tuberculosis is
still unclear. However, in Escherichia coli, a cluster of muta-
tions in rpoB gene located between codons 563 and 572 has
been shown to cause RMP resistance in vitro (9).
The results were never difficult to interpret: the most fre-
quently detected mutation (Leu-531), which is not always eas-
ily detectable by means of SSCP analysis (17), leads to the
formation of an unmistakable three-band pattern (Fig. 1).
DG-DGGE analysis of the PCR products obtained from
pathological clinical samples was also performed. The rpoB
PCR protocol used in this study seems to be less sensitive than
a similar protocol we optimized in order to produce a shorter
sequence for SSCP analysis (17) and also less sensitive than the
single-tube heminested protocol used by Whelen et al. (23).
The possibility of fragmentation of the DNA target contained
in a clinical sample stored at 220°C for a long time could
partially justify the less sensitive nature of a method designed
to amplify a considerably longer sequence.
In conclusion, the use of DG-DGGE analysis can reasonably
be considered a valid alternative to other indirect methods of
detecting sequence variations in the rpoB core region. Its ex-
cellent reproducibility, together with the fact that it is easy to
perform, means that it can be used in clinical microbacteriol-
ogy laboratories.
We are grateful to Cecilia Gelfi of ITBA (CNR, Milan, Italy) for
excellent technical assistance.
TABLE 3. DG-DGGE analysis of CSF samples, patient data, the results obtained by two PCR protocols, PCR–DG-DGGE patterns,










phenotypeTotal Positive byIS6110 PCR
Positive by rpoB PCR
(evaluable by DG-DGGE)
Confirmed CNS TBf by
CSF-positive culture
1 32 Md 2 2 1 Wild type Susceptible
2 72 M 2 2 2 Wild type Susceptible
3 42 Fd 5 4 4 Wild type Susceptible
4 31 F 2 1 1 Wild type Susceptible
5 63 M 4 3 1 Wild type Susceptible
6 30 M 1 1 1 Wild type Susceptible
7 30 Md 1 1 1 Wild type Not available
8 35 Md 1 1 1 Abnormal (A) Resistant
9 30 Md 1 1 1 Abnormal (B) Resistant
10 59 Md 1 1 1 Abnormal (A) Resistant
11 56 Md 1 1 1 Abnormal (A) Resistant
12 27 Fd 2 2 0 Susceptible
13 40 F 1 1 0 Susceptible
14 34 Md 1 1 0 Resistant
15 30 Md 2 2 0 Resistant
16 83 Md 1 1 0 Not available
17 80 F 2 2 0 Not available
Confirmed CNS TB at
autopsy
18 30 Md 1 1 1 Abnormal (B) Resistante
19 33 Md 3 3 2 Abnormal (B) Resistante
20 36 Md 2 2 1 Abnormal (B) Resistante
Highly probablec
21 27 Fd 2 2 2 Wild type Not available
22 30 Fd 2 2 1 Abnormal (C) Resistante
23 51 F 2 1 1 Abnormal (C) Not available
24 75 M 1 1 1 Wild type Not available
25 30 Md 1 1 1 Wild type Not available
26 29 M 1 1 1 Wild type Not available
27 29 Md 1 0 0 Not available
28 41 F 2 0 0 Not available
Total no. of samples
(no. of patients)
48 (28) 41 (26) 26 (20)
% of positive samples
(% of patients)
85.4 (92.9) 54.2 (71.4)
a M, male; F, female.
b Three different abnormal patterns were found and classified as A, B, or C.
c CNS TB was considered highly probable because the suggestive clinical picture was accompanied by at least three of the following supporting tests: (i) compatibly
abnormal CSF findings; (ii) computed tomography findings suggesting CNS TB; (iii) evidence of tuberculosis outside the CNS; (iv) clinical response to antituberculosis
therapy.
d Patients coinfected with human immunodeficiency virus.
e Susceptibility testing determined with isolates cultured from respiratory specimens.
f TB, tuberculosis.
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